See What HealthDay Can Do For You
Contact Us

Edarbi Approved for Treatment of Hypertension

But shouldn't be taken by pregnant women

MONDAY, Feb. 28 (HealthDay News) -- Edarbi (azilsartan medoxomil) has been approved by the U.S. Food and Drug Administration to treat adults with hypertension.

Clinical trials showed Edarbi was more effective in lowering high blood pressure over 24 hours than two previously FDA-approved drugs, Diovan (valsartan) and Benicar (olmesartan), the agency said in a news release.

Edarbi helps lower blood pressure by blocking the action of angiotensin II, the FDA said. The most common adverse reaction was diarrhea, maker Takeda Pharmaceutical North America said in a statement.

Edarbi has a boxed label warning that it shouldn't be used by women who are pregnant. If a woman becomes pregnant while taking the drug, it should be discontinued as soon as possible, the FDA stressed.

Takeda is based in Deerfield, Ill.

More information

The U.S. National Heart Lung and Blood Institute has more about high blood pressure.

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.